6533b82ffe1ef96bd1295dca
RESEARCH PRODUCT
Natural history of malignant bone disease in renal cancer: final results of an Italian bone metastasis survey.
Bart O. WilliamsSantini DanieleGiuseppe ProcopioPorta CamilloToni IbrahimBarni SandroMazzara CalogeroAndrea FontanaAlfredo BerrutiBerardi RossanaVincenzi BrunoOrtega CinziaOttaviani DavideCarteni GiacomoLanzetta GaetanoVirzì VladimirMatteo SantoniSilvestris Nicola Maria Antonietta SatolliCollovà ElenaRusso AntonioBadalamenti Giuseppe Stefano Luzi Fedeli Francesca Maria TancaAdamo VincenzoEvaristo MaielloRoberto SabbatiniFelici AlessandraSaverio CinieriTonini GiuseppeSergio Bracardasubject
OncologyMaleAnatomy and PhysiologyBone diseaseEpidemiologySettore MED/06 - Oncologia Medicamedicine.medical_treatmentMetastasisMetastasisbone metastasesRenal cell carcinomaBasic Cancer ResearchMedicineMusculoskeletal SystemMultidisciplinaryDiphosphonatesrenal cell carcinoma bone metastasis zoledronic acidQRBone metastasisKidney NeoplasmsOncologyItalyObservational StudiesDisease ProgressionMedicineFemaleCancer Epidemiologymedicine.drugResearch Articlemedicine.medical_specialtyClinical Research DesignSciencerenal cancerBone NeoplasmsInternal medicineHumansBonerenal cancer; bone metastasesRetrospective Studiesbusiness.industryRenal Cell CarcinomaCancerCancers and NeoplasmsBone fracturemedicine.diseaseSurgeryRadiation therapyGenitourinary Tract TumorsZoledronic acidbusinessdescription
BackgroundBone metastasis represents an increasing clinical problem in advanced renal cell carcinoma (RCC) as disease-related survival improves. There are few data on the natural history of bone disease in RCC.Patients and methodsData on clinicopathology, survival, skeletal-related events (SREs), and bone-directed therapies for 398 deceased RCC patients (286 male, 112 female) with evidence of bone metastasis were statistically analyzed.ResultsMedian time to bone metastasis was 25 months for patients without bone metastasis at diagnosis. Median time to diagnosis of bone metastasis by MSKCC risk was 24 months for good, 5 months for intermediate, and 0 months for poor risk. Median number of SREs/patient was one, and 71% of patients experienced at least one SRE. Median times to first, second, and third SRE were 2, 5, and 12 months, respectively. Median survival was 12 months after bone metastasis diagnosis and 10 months after first SRE. Among 181 patients who received zoledronic acid (ZOL), median time to first SRE was significantly prolonged versus control (n = 186) (3 months vs 1 month for control; PConclusionsRCC patients with bone metastasis are at continuous risk of SREs, and in this survey ZOL effectively reduced this risk.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2013-12-30 |